Relmada Therapeutics (RLMD) Other financing activities (2014 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Other financing activities of $160.0 million for Q1 2026, up 64743.75% quarter-over-quarter from $246747.0 in Q1 2024.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Other financing activities (2014 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Other financing activities for 8 consecutive years, with $160.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $160.0 million; the TTM figure through Mar 2026 stood at $160.0 million (changed N/A YoY), while the FY2024 annual figure was $246747.0, up 150.6% from the prior year.
- Other financing activities climbed to $160.0 million in Q1 2026 per RLMD's latest filing, from $246747.0 in the prior quarter.
- Across five years, Other financing activities topped out at $160.0 million in Q1 2026 and bottomed at -$191636.0 in Q3 2022.
- Historically, Other financing activities has averaged $32.2 million across 3 years, with a median of $300006.0 in 2022.
- On a YoY basis, Other financing activities climbed as much as 163.12% in 2022 and fell as far as 111.98% in 2022.
- Relmada Therapeutics' Other financing activities stood at -$191636.0 in 2022, then soared by 228.76% to $246747.0 in 2024, then jumped by 64743.75% to $160.0 million in 2026.
- Business Quant data shows RLMD's Other financing activities at $160.0 million in Q1 2026, $246747.0 in Q1 2024, and -$191636.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -159.90 Mn |
| Mar 31, 2026 | 160.00 Mn |
| Mar 31, 2024 | 246,747.00 |
| Dec 31, 2022 | 36,251.00 |
| Sep 30, 2022 | 332,916.00 |
| Jun 30, 2022 | 595,350.00 |
| Mar 31, 2022 | 300,006.00 |
| Dec 31, 2021 | 182.53 Mn |
| Sep 30, 2021 | 175,014.00 |
| Jun 30, 2021 | 481,449.00 |
| Mar 31, 2021 | 1.46 Mn |
| Dec 31, 2020 | 870,110.00 |
| Sep 30, 2020 | 1.57 Mn |
| Jun 30, 2020 | 2.58 Mn |
| Mar 31, 2020 | 3.04 Mn |
| Sep 30, 2019 | 450,000.00 |
| Jun 30, 2019 | 12.58 Mn |
| Mar 31, 2019 | 1.73 Mn |
| Jun 30, 2015 | -19,201.00 |
| Mar 31, 2015 | 10,000.00 |